Mediwound (MDWD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MediWound Ltd. has reported a robust second quarter in 2024 with the completion of a new NexoBrid manufacturing facility and a strategic $25 million investment from Mölnlycke Health Care. The company has also secured €16.25 million in European Innovation Council funding to accelerate the development of EscharEx for diabetic foot ulcers, with anticipated revenue growth. These developments, along with the initiation of a Phase III study for venous leg ulcers, signify MediWound’s strong position in the enzymatic therapeutics market for tissue repair.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
